Greywolf Therapeutics

Greywolf Therapeutics is a private, preclinical-to-clinical stage biotech based in Oxford, UK, developing a first-in-class therapeutic approach focused on modulating Signal 1 of the T cell activation cascade. The company's core technology involves small molecules that 'flick a switch' inside cells to alter their antigen presentation, thereby enabling or suppressing T cell recognition. With a lead oncology candidate (GRWD5769) showing proof-of-mechanism in Phase 1/2 trials and active discovery programs in autoimmunity and virology, Greywolf is positioning itself as a pioneer in a new therapeutic branch of immunology. The company is pre-revenue and backed by an expert team focused on addressing significant unmet medical need through fundamental immune system retuning.

Novel small molecule antigen modulation technology designed to pharmacologically control Signal 1 of the T cell activation cascade by altering antigen presentation on MHC molecules inside cells, thereby changing a cell's appearance to the immune system.

Greywolf operates in a competitive immuno-oncology and immunology space but claims a unique niche by targeting antigen presentation (Signal 1). Direct competitors are scarce, but it competes for funding and mindshare with all companies developing T-cell modulating therapies. Its main competition comes from established approaches like checkpoint inhibitors (Signal 2), cytokine therapies, and cell therapies, against which it must demonstrate superior or complementary efficacy.